Pipeline update - following an interim analysis the studies with bifeprunox for the treatment of schizophrenia is discontinued

H. Lundbeck A/S (Lundbeck) today announced the joint decision with
its partner Solvay Pharmaceuticals, B.V. (Solvay) to stop all joint
R&D activities for Solvay's compound bifeprunox in development for
maintenance treatment of schizophrenia.

The companies made this decision after evaluating the recent results
from an interim analysis of pooled data intended for a possible
extension of the ongoing clinical phase III trial programme. Efficacy
data did not support pursuing the existing development strategy of
stabilisation of non-acute patients with schizophrenia. Therefore,
Lundbeck and Solvay judge that it would be futile to continue the
studies.

The content of this release will have no influence on the Lundbeck
Group's financial result for 2009.

About bifeprunox
Bifeprunox, a partial dopamine and serotonin 5-HT1A agonist designed
to stabilize dopamine function in the brain, has been studied in more
than 2,500 patients with schizophrenia in 14 efficacy and safety
studies conducted throughout the world. Solvay is the originator of
the compound.


Lundbeck contacts


Investors:                   Media:

Jacob Tolstrup               Mads Kronborg
Director, IR & Communication Media Relations
+45 36 43 30 79              +45 36 43 28 51

Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26

Magnus Thorstholm Jensen
Investor Relations Officer
+45 36 43 38 16



About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international
pharmaceutical company highly committed to improve the quality of
life for people suffering from central nervous system (CNS)
disorders. For this purpose Lundbeck is engaged in the research and
development, production, marketing and sale of pharmaceuticals across
the world, targeted at disorders like depression and anxiety,
schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's
diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark,
and employs today over 5,500 people worldwide. Lundbeck is one of the
world's leading pharmaceutical companies working with CNS disorders.
In 2008, the company's revenue was DKK 11.3 billion (approximately
EUR 1.5 billion or USD 2.2 billion). For more information, please
visit www.lundbeck.com.